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Abstract
Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis
(JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC).
Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and
approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious
infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC
by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI
resulted by matching the adjudicated infections with the provisional list of OI.
Results: A total of 772 infectious events in 572 eligible patients, of which 335 serious/severe/very severe non-OI
and 437 OI (any intensity/severity), according to the provisional list, were retrieved. Six hundred eighty-two of 772
(88.3%) were adjudicated as infections, of them 603/682 (88.4%) as common and 119/682 (17.4%) as OI by the SAC.
Matching these 119 opportunistic events with the provisional list, 106 were confirmed by the SAC as OI, and
among them infections by herpes viruses were the most frequent (68%), followed by tuberculosis (27.4%). The
remaining events were divided in the groups of non-OI and possible/patient and/or pathogen-related OI.
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Conclusions: We found a significant number of OI in JIA patients on immunosuppressive therapy. The proposed
list of OI, created by consensus and validated in the Pharmachild cohort, could facilitate comparison among future
pharmacovigilance studies.
Trial registration: Clinicaltrials.gov NCT 01399281; ENCePP seal: awarded on 25 November 2011.
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Background
With the advent of biologic disease-modifying anti-
rheumatic drugs (DMARDs), in a chronic condition like
juvenile idiopathic arthritis (JIA), regulatory authorities
such as the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) have demanded from
pharmaceutical companies and clinical researchers to
evaluate the long-term safety of drugs used in children en-
rolled in phase II–III clinical trials [1–16]. Due to the lim-
ited number of patients enrolled in these trials [17],
clinical researchers have devoted their work to the imple-
mentation of national and international registries [18–28]
or to the analysis of insurance claim data [29–31].
During their development, all children experience a nat-
ural rate of infections compared to adults. Treatments in
JIA with synthetic and biologic DMARDs are expected to
increase the frequency of common infections and the risk
of serious and opportunistic infections (OI) [23, 30–34],
including especially tuberculosis in some geographic areas
[35–37]. In order to tackle the long-term safety and effi-
cacy evaluations, the Paediatric Rheumatology INter-
national Trials Organization (PRINTO) started in 2011
the “Pharmacovigilance in Juvenile Idiopathic Arthritis pa-
tients” (Pharmachild), an observational international regis-
try supported by a European Union grant [38, 39].
Recent literature seems to confirm the high incidence
of infections among JIA patients treated with immuno-
suppressants [21], but conclusive data are not available,
yet. In particular, little evidence exists about the role of
JIA or its immunosuppressive therapy in acquiring OI.
Several studies in the literature have the objective to
define and classify OI, for example in HIV or in cancer
patients [40–43]. In rheumatology, Winthrop and col-
leagues [32] were the first to convene a consensus meet-
ing in 2015 to review the published literature on OI in
patients with immune-mediated diseases treated with
biologic DMARDs, in order to provide consensus rec-
ommendations for their evaluation in the context of
clinical trials and observational studies.
Primary objectives of the present study were to derive
a consensus-based list of opportunistic pathogens for
use in children with JIA and confirm its role in identify-
ing OI through the evaluation of the infectious events
reported in Pharmachild registry by an independent
Safety Adjudication Committee (SAC).
Methods
Pharmachild
The Pharmachild registry (project number 260353) in-
volves 86 participating PRINTO (www.printo.it) centers
in 32 countries [38] and the Paediatric Rheumatology
European Society (PRES at www.pres.eu), with the aim
to (1) monitor children with JIA for disease activity and
comorbidity; (2) compare the long-term incidence rates
of moderate, severe, and very severe adverse events (AE)
and serious AE (SAE); and (3) assess the long-term effi-
cacy of biologic and synthetic DMARDs in JIA. The
Pharmachild registry contains both a retrospective and a
prospective cohort. In brief, the retrospective cohort in-
cludes data from patients under treatment or previously
treated with DMARDs obtained by one-time clinical
chart review for safety events and complete drug expos-
ure since disease onset to last available follow-up; the
prospective cohort includes all cases newly treated with
DMARDs since enrollment in the registry and cases still
under treatment with any drug. In case of repeated
events (e.g., infection with multiple reporting in the
registry for the follow-up evaluation), only the initial
event was considered. Full details of the registry method-
ology are available elsewhere [39].
Study design
The study was divided into 5 main steps (additional figure 1).
Step 1: Provisional listing of opportunistic pathogens/
infection presentations
The study Steering Committee (SC) included two PhD
medical doctors (GG and JS), two certified Medical Dic-
tionary for Regulatory Activities (MedDRA) coders (CP,
LV), 3 biostatisticians (AP, FB, FB), and two Senior re-
searchers (NW, NR).
The SAC was organized as an independent group of 5
physicians: 2 pediatric infectious disease specialists (EC
and AG) and 3 pediatric rheumatologists (GH, HIH,
DL), who have experience and expertise in the diagnosis
and treatment of children with infectious or rheumatic
diseases.
The SC starting point was the prior work by Winthrop
et al. [32], an international consensus committee (infec-
tious disease, public health, and pulmonary physicians
and rheumatologists) that recommended a list of definite
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and probable OI after systematic review of literature on
immune-mediated disorders (including JIA), and a con-
sensus process. This list was discussed, modified, and
approved by consensus by the SAC, through three sub-
sequent Delphi web rounds, with the final result of a list
of opportunistic pathogens/presentations for use in im-
munosuppressed children with JIA. In the first round,
SAC members worked independently from each other,
while during the second round, they could also revise
their responses based on the review of comments from
the other members. Final consensus was reached
through a dedicated teleconference (moderator NR).
The SC then integrated the review of the literature
with more recent evidence on OI in JIA [31, 44, 45] and
prepared a provisional list of OI pathogens, then
matched them with the MedDRA Preferred Terms (PT)
in order to retrieve correctly the cases from the Pharma-
child database. This provisional list was not shared with
the SAC members as it was used only for data retrieval
(see next step).
Step 2: Retrieval of infections in Pharmachild
For the Pharmachild study, the treating physicians re-
ported online in the registry database all AEs from the
disease onset to the last available follow-up visit. All
terms contained in the MedDRA System Organ Class
(SOC) “Infections and infestations” were considered in
Pharmachild as Events of Special Interest (ESI) and clas-
sified in two different ESI sub-groups, named “tubercu-
losis” and “targeted infections (Epstein-Barr virus,
cytomegalovirus, papilloma virus, herpes zoster primary
and reactivation, and opportunistic infections).”
According to the Pharmachild protocol, all events
(AEs and ESIs) of at least moderate intensity and all
SAEs were collected. AEs and ESIs were coded initially
by the treating physicians during data entry using the
MedDRA dictionary, then recoded, if needed, by
PRINTO-certified MedDRA coders and revised by the
PRINTO medical monitor (JS), based on the most
current version of MedDRA.
All infectious events (both initial and follow-up) in the
MedDRA system organ class (SOC) (additional figure 2)
“Infection and infestations” in Pharmachild as of January
2017 were retrieved (Fig. 1).
Step 3: Adjudication of infections by the SAC
A standard operating procedure (SOP) described the
work to be done by the SAC. In brief, the SAC adjudica-
tion process included all the opportunistic events in the
provisional list of OI derived by step 1 (any grade of se-
verity) plus the non-OI infections of at least severe in-
tensity and all serious infections from both retrospective
and prospective charts.
The list of the events to be adjudicated by the SAC
was provided in a dedicated external area of the
PRINTO/Pharmachild website, with access through se-
cure personal username and password.
The SAC members who reviewed all eligible cases
(presented in numerical order by patient’s code) did not
participate in the data collection in Pharmachild.
The complete patients’ data were available for the SAC
members: (1) demographic characteristics of the patient
(with personal data encrypted), (2) ILAR category of JIA,
(3) laboratory and clinical information, (4) complete
drug therapy with whole drug exposure for synthetic
and biologic DMARDs since disease onset to the last
available observation, (5) concurrent medications at the
time of the infectious event, and (6) full AE report plus
ESI-specific form for infections. In addition, JIA disease
activity and a damage measure were available for pro-
spective visits. The SAC members had the possibility to
access the complete clinical information in a read-only
mode, with no possibility to modify the original data. A
numeric code, without any patient or center identifier
and no a priori categorization of AE as OI, was provided
to decrease potential bias during the adjudication
exercise.
The SAC mandate was to evaluate each infectious
case, based on the whole patient’s history available in
Pharmachild, by answering 5 questions: (1) Based on the
information provided, do you confirm that this patient
had an infection?; (2) Is this infection common?; (3) Is
this an opportunistic infection?; (4) Was the treatment
appropriate for the infection?; (5) Could the event be
possibly related to any of the drug(s) taken at the time
of the event? The study SC was available to provide any
additional information related to the event and required
by the SAC at any time.
The consensus among the SAC members was defined
as an agreement of at least 3 out of 5 (60%) members,
on the first 3 out of 5 adjudication questions (“Is this an
infection?,” “Is it common?,” “Is it opportunistic?”). Ini-
tially, the SAC members worked independently from
each other, while in the next phase, for all cases without
consensus, each member could access the evaluations of
the other SAC members.
Step 4: Analysis of the Pharmachild registry
Step 4 was designed to evaluate, in an evidence-based
fashion, the frequency of those events in the Pharma-
child registry classified as infections by consensus among
the SAC and to assign a final MedDRA code (High Level
Term (HLT)/PT) to the event. In case of discrepancies
in the categorization, after PRINTO and medical moni-
tor (JS) check, a third independent examiner (GG) re-
evaluated the individual case and assigned the final Med-
DRA code (HLT/PT).
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Step 5: Final evidence-based listing of opportunistic
pathogens/infection presentations
In this step, all the infectious events adjudicated by the
majority of the SAC in Pharmachild were matched by
MedDRA PT term with the provisional list of OI (see
step 1) and divided in three groups: “confirmed OI,” if
there was full agreement between the SAC and the
provisional list of OI; “confirmed non-OI,” for the events
adjudicated as non-OI by the SAC and missing in the
provisional list; “possible/patient and/or pathogen-
related OI,” for the remaining events in Pharmachild
that could be possibly considered opportunistic depend-
ing on the physician’s evaluation of the patient history
and by the detection of the specific pathogen causing
the disease.
Statistical analysis
Descriptive statistics were reported in terms of absolute
frequencies and percentages for qualitative data. Quanti-
tative data were described in terms of median values and
inter-quartile range (IQR) values due to their non-
normal (Gaussian) distribution.
Results
Step 1: Provisional list of opportunistic pathogens/
presentations
After the three web Delphi rounds, the probable and
definite definitions of OI were agreed with one major
change by 5/5 (100%) of the SAC [32]. In particular, the
definition of definite OI was confirmed, while for prob-
able infections, it was integrated with the following: “In
Fig. 1 Flowchart of the Pharmachild population with infectious events
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case of the unusually severe course of infection due to a
common pathogen with usually mild disease the patho-
gen might tentatively be considered opportunistic in a
patient with impaired immune function.” Two definite
categories of pathogens/presentations were modified by
the SAC, while twelve were added in the provisional list
of probable OI from the literature and matched with the
HLT/PT MedDRA dictionary; none of the infections
already included in the list by Winthrop et al. [33] was
removed.
Table 1 shows the provisional list of pathogens/pre-
sentations, with the corresponding HLT terms according
to MedDRA dictionary.
Step 2: Retrieval of infections in Pharmachild
Among the 8274 patients enrolled in the Pharmachild
registry as of January 2017, 895 (10.8%) patients had ex-
perienced 1585 infections. A total of 772 events (48.7%)
in 572 patients (Fig. 1 and step 3 of the “Methods” sec-
tion) were eligible for the evaluation by the SAC, of
which 437 were defined as preliminary OI, as per the
provisional list of opportunistic pathogens/presentations,
and 335 as very severe/severe or serious non-OI events
(Fig. 1).
The baseline characteristics of the 572/895 (63.9%) ad-
judicated patients are reported in Table 2 in comparison
with those who were not adjudicated. Among the 895
patients with infections, about 85% were from Europe,
specifically 29.3% from Italy and 23.6% from the
Netherlands, while the remaining patients were distrib-
uted among Russia (8%), South America (4%), Middle
East, and India (3%). The adjudicated group was repre-
sented by younger patients, with longer disease duration,
higher frequency of systemic JIA, and more frequent use
of systemic glucocorticoids.
Step 3: Adjudication of infections by the SAC
A total of 689/772 (89.2%) events achieved consensus
(3/5 SAC members) on the first 3 adjudication ques-
tions, and of these, 682 (99.0%) were considered as infec-
tions by the SAC and included in the analysis (Table 3).
The majority of the 682 infections were considered com-
mon (88.4%), with 119 (17.4%) classified as opportunistic
by the SAC after evaluation of the whole patient’s his-
tory. The consensus on the last 2 questions was more
difficult to reach. Regarding the fourth question on the
appropriateness of the treatment for the infection, con-
sensus was achieved for 484 (77.1%) events, while for
140 (22.3%) of the cases, it was impossible to determine
the suitability of the anti-infective treatment.
Similarly, for the fifth question about the possible rela-
tionship between the infection and the related treat-
ment(s) for JIA, the lack of consensus increased up to
279 (41%). For 307/403 (76.2%) cases for which there
was consensus, the SAC considered the drug(s) possibly
related to the event. When we considered the drugs ad-
ministered at the time of infection, the association of 1
biologic (more commonly etanercept or adalimumab)
plus 1 synthetic DMARD was the most frequently re-
ported (32% of the cases), followed by methotrexate
alone (21%) and etanercept alone (20.3%), and finally by
the association of either 1 biologic plus 1 synthetic
DMARD plus systemic glucocorticoids (9%) or 1 syn-
thetic DMARD plus systemic glucocorticoids (3.7%).
Step 4: Analysis of the infections according to MedDRA
dictionary
The evaluation of the Pharmachild registry conducted by
the SAC led to the adjudication of the 682 infections
corresponding to 53 HLTs and 153 PTs. For 92 (60%)
PTs, the expert committee confirmed the same PT used
by the Pharmachild Medical Monitor, while for the
remaining 40%, discrepancies were solved by the study
SC after re-evaluation of the individual cases. The final
number of HLTs was 50, with corresponding 149 PTs,
showed in details with the frequency of the events in the
additional table 1.
Step 5: Final evidence-based listing of opportunistic
pathogens/infection presentations
After matching the adjudicated events with the
provisional list of OI, among the 682 events, 106 (15.5%)
for 22 PT were classified as “confirmed OI,” 274 (40.2%)
for 89 PT were classified as “confirmed non-OI,” and
302 (44.3%) for 38 PT were classified as “possible/patient
and/or pathogen- related OI.”
Table 4 shows the frequency of the 106 “confirmed
OI” by HLT/PT in 93 patients. Regarding pathogens,
herpes viral infections resulted the most frequent HLT/
PT category, with 72 events (68% of the total confirmed
OI), mostly represented by herpes zoster infection (66/
72, 91.6%). Among the 64 patients with 72 confirmed
herpes zoster infections, 35/64 (54.7%) had varicella in
the past history and later developed herpes zoster (34
patients) and herpes zoster oticus (1 patient). One out of
35 patients, who had been vaccinated against varicella
zoster had varicella in the past, and later zoster infection.
Two additional patients had been vaccinated for varicella
among those who developed zoster infection without
having varicella reported in the history. Tuberculosis,
Candida, papilloma, and Pneumocystis followed with a
frequency higher than 3%. Among the 4 papilloma viral
infections, affecting 2 patients in their history, no one
was preceded by HPV vaccination. Of all the 29 Myco-
bacterium tuberculosis infections in Pharmachild
(additional table 1), only 11/29 (38%) were “confirmed
OI,” mostly in female patients (70%), at a median age of
5.2 years, not previously vaccinated with BCG, with
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Table 1 Provisional list of pathogens/presentations and MedDRA HLT term approved by consensus by the SAC
Opportunistic infections definitions/pathogens MedDRA HLT
Definition of definite opportunistic infection in children with JIA
1. Generally does not occur in the absence of immunosuppression and whose presence suggests
a severe alteration in host immunity OR
2. Can occur in patients without recognized forms of immunosuppression, but whose presence
indicates a potential or likely alteration in host immunity
List of definite pathogens and/or presentations of specific pathogens
Aspergillosis (invasive disease only) Aspergillus infections
Bartonellosis (disseminated disease only) Bartonella infections
BK virus disease including PVAN BK virus infection
Blastomycosis Blastomyces infections
Candidiasis (invasive disease or pharyngeal) Candida infections
Coccidioidomycosis Coccidioides infections/Paracoccidioides
infections
Cryptococcosis Cryptococcal infections
Cytomegalovirus disease with onset at age > 1month: pneumonia (CMV in BAL), colitis,
CNS disease (CMV in CSF), liver (biopsy), retina (confirmed by ophthalmologist), nephritis,
myocarditis, pancreatitis
Cytomegaloviral infections
HBV reactivation Hepatitis viral infections
Herpes simplex (invasive disease only) Herpes viral infections
Herpes zoster (any form) Herpes viral infections
Histoplasmosis Histoplasma infections
Legionellosis Legionella infections
Listeria monocytogenes (invasive disease only) Listeria infections
Nocardiosis Nocardia infections
Non-tuberculous mycobacterium disease Atypical mycobacterial infections
Other invasive fungi: Mucormycosis (zygomycosis) (Rhizopus, Mucor and Lichtheimia), Scedosporium
/Pseudallescheria boydii, Fusarium
Fungal infections NEC
Pneumocystis jirovecii Pneumocystis infections
Post-transplant lymphoproliferative disorder (EBV) Epstein-Barr viral infections
Progressive multifocal leucoencephalopathy Polyomavirus infections
Salmonellosis (invasive disease only) Salmonella infections
Strongyloides (hyperinfection syndrome and disseminated forms only) Nematode infections
Toxoplasmosis of central nervous system, onset at age ≥ 1month; Disseminated toxoplasmosis,
visceral toxoplasmosis
Toxoplasma infections
Tuberculosis Tuberculous infections
Definition of probable opportunistic infection
Published data is currently lacking, but expert opinion believes that risk is likely elevated in the setting
of DMARD therapy. In case of the unusually severe course of infection due to a common pathogen with
usually mild disease the pathogen might tentatively be considered opportunistic in a patient with
impaired immune function. Below there is a non-exhaustive list of possible pathogens
List of probable pathogens and/or presentations of specific pathogens
Campylobacteriosis (invasive disease only) Campylobacter infections
Cryptosporidium species (chronic disease only) Cryptosporidia infections
Enterovirus chronic encephalitis Enteroviral infections NEC
Giardia, Isospora: chronic (> 1month) diarrhea Giardia infections/Isospora infections
HCV progression Hepatitis viral infections
Human Herpes Virus (HHV6–7): pneumonia, encephalitis Herpes viral infections
Human Herpes Virus (HHV8): kaposi sarcoma Herpes viral infections
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pulmonary or disseminated presentations. The
remaining were either latent tuberculosis or not well-
specified contact with the pathogen, classified by the
SAC as “possible/patient and/or pathogen-related OI.”
The majority of the “confirmed OI” was reported in Eur-
ope (75.5%), while 11.3% was reported in Russia, 9.4% in
Brazil, and 1.9% in India and Israel. These events oc-
curred after a median period of 5.3 years from disease
onset (IQR 3.4–9.2). Scanty data were reported on the
immune status of the patients with “confirmed OI” at
the moment of infection and soon afterwards. For 17.8%
(10/93) of the patients with “confirmed OI,” there was
evidence of lymphocytes below 500/μl only in 2 patients
with cytomegalovirus and herpes zoster infection. No
other immunological abnormalities could be observed
(data not shown).
When we considered the most frequent “confirmed
OI,” namely herpes zoster infections, Candida infections,
and HPV infections, we noticed that patients were
mostly female, with a median age at event onset between
5 and 6 years, except for HPV infection, with a median
age at the event onset during adolescence (median 14.5
years, IQR 11.9–17.1).
The most frequent “confirmed OI,” herpes zoster and
tuberculosis, occurred in the majority of the cases, dur-
ing treatment with biologics (70.8% and 90.9%, respect-
ively) and methotrexate (56.9% and 90.9%, respectively),
followed by systemic glucocorticoids (19.4% and 27.3%,
respectively). For Candida, glucocorticoids were re-
ported in half of the cases, followed by biologics. By ex-
cluding one patient who got one steroid pulse at high
dose and developed disseminated tuberculosis, the
remaining patients with “confirmed OI” received a me-
dian dose of prednisone of 15 mg/day concomitantly to
the infection. Details on the remaining infections can be
found in the additional table 2.
Table 5 reports the frequency of “confirmed non-OI”
and “possible/patient and/or pathogen-related OI,” after
removing 218 infections for which PTs did not include a
specific pathogen (the complete list of “confirmed non-
OI” and “possible/patient and/or pathogen- related OI”
is presented in additional table 1). Among the 274 infec-
tions classified as “confirmed non-OI,” only 59 (21.5%)
were related to a specific pathogen, most frequently in-
fluenza virus, Streptococcus, Staphylococcus, and Escheri-
chia. Conversely, almost all the infections classified as
“possible/patient and/or pathogen-related OI” (299/302,
99%) were related to a specific pathogen.
Most of the herpes virus infections (193/299, 64.5%)
were classified as “possible patient- and/or pathogen-
related OI” with a different clinical presentation com-
pared to the previous group of “confirmed OI.” In par-
ticular, varicella was the most common herpetic
manifestation in this group, with 155/299 (51.8%) cases,
followed by herpes simplex infections. Epstein-Barr virus
infections were reported in 38/299 cases (12.7%),
Table 1 Provisional list of pathogens/presentations and MedDRA HLT term approved by consensus by the SAC (Continued)
Opportunistic infections definitions/pathogens MedDRA HLT
Human metapneumovirus (hMPV): pneumonia, ARDS Viral infections NEC
Human Papilloma Virus (HPV): extensive warts Papilloma viral infections
Human respiratory syncytial virus (RSV): pneumonia with onset > 6months of age Respiratory syncytial viral infections
Legionellosis Legionella infections
Leishmaniasis (Visceral only) Leishmania infections
Microsporidiosis Protozoal infections NEC
Molluscum contagiosum: chronic, disseminated Molluscum contagiosum
Paracoccidioides infections Paracoccidioides infections
Parvovirus B19: pure red cell aplasia Parvoviral infections
Penicillium marneffei Fungal infections NEC
Rota-Arena-Norovirus: chronic (> 1month) diarrhea Rotaviral infections/Arenaviral
infections/Caliciviral infections
Shigellosis (invasive disease only) Shigella infections
Sporothrix schenckii Sporothrix infections
Trypanosoma cruzi infection (Chagas’ disease) (disseminated disease only) Trypanosomal infections
Varicella: encephalitis (excluding cerebellitis), hepatitis, pneumonia Herpes viral infections
Vibriosis (invasive disease due to Vibrio vulnificus) Vibrio infections
West Nile, Usutu: chronic encephalitis Flaviviral infections
In bold, those pathogens/presentations modified by the Safety Adjudication Committee (SAC) after consensus and literature review on the basis of Winthrop
et al.’s paper [32]. PVAN polyomavirus-associated nephropathy, BAL bronchoalveolar lavage, CNS central nervous system, CSF cerebrospinal fluid, DMARD disease-
modifying anti-rheumatic drug, CMV cytomegalovirus
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classified as infectious mononucleosis in 13 cases (4.3%).
Latent tuberculosis accounted for 12/299 (4.1%) cases,
followed by a few cases of tuberculosis, also with lymph
node involvement included in this group. The remaining
events of “possible/patient and/or pathogen-related OI”
affected less than 3% of the cases.
Discussion
An evidence-based list of opportunistic pathogens with
the related MedDRA classification in immunosuppressed
children with JIA has been derived by the combination
of consensus among a panel of pediatricians with expert-
ise in rheumatology and infectious diseases, and the ana-
lysis of the Pharmachild international registry in JIA
Table 2 Demographic and clinical characteristics of the Pharmachild patients with infections
Data are n (%) or medians
with IQR range
Patients adjudicated*
(N = 572)
Patients not
adjudicated* (N = 323)
Patients with
infections (N = 895)
P (patients adjudicated
vs not adjudicated)
Females 388 (67.8%) 241 (74.6%) 629 (70.3%) 0.033
Age at onset 3.1 (1.7–6.7) 4.1 (2.1–8.5) 3.5 (1.9–7.3) 0.001
Age at JIA diagnosis 3.7 (2.1–7.5) 4.9 (2.4–9.5) 4.1 (2.2–8.1) 0.001
Disease duration at last FU 7.6 (5.0–11.1) 5.8 (3.1–10.3) 7.1 (4.2–10.8) < 0.001
JIA category 0.004
Systemic 120 (20.9%) 37 (11.4%) 157 (17.5%)
Oligo persistent 101 (17.7%) 80 (24.8%) 181 (20.2%)
Oligo extended 100 (17.5%) 50 (15.5%) 150 (16.8%)
Polyarticular RF- 132 (23.1%) 84 (26.0%) 216 (24.1%)
Polyarticular RF+ 19 (3.3%) 15 (4.6%) 34 (3.8%)
Psoriatic 25 (4.4%) 8 (2.5%) 33 (3.7%)
Enthesitis 36 (6.3%) 21 (6.5%) 57 (6.4%)
Undifferentiated 39 (6.8%) 28 (8.7%) 67 (7.5%)
Systemic glucocorticoids 336 (58.7%) 154 (47.7%) 490 (54.7) 0.001
Synthetic DMARDs
Methotrexate 532 (93.0%) 289 (89.5%) 821 (91.7%) 0.065
< 0.001
Cyclosporine 90 (15.7%) 13 (4.1%) 103 (11.5%) < 0.001
Sulfasalazine 66 (11.5%) 28 (8.7%) 94 (10.5%) 0.179
Leflunomide 40 (7.0%) 28 (8.7%) 68 (7.6%) 0.364
Azathioprine 17 (3.0%) 6 (1.9%) 23 (2.6%) 0.312
Hydroxychloroquine 14 (2.4%) 9 (2.8%) 23 (2.6%) 0.758
Thalidomide 7 (1.2%) 2 (0.6%) 9 (1.0%) 0.501
Biologic DMARDs
Etanercept 298 (52.1%) 126 (39.0%) 424 (47.4%) < 0.001
Adalimumab 178 (31.1%) 82 (25.4%) 260 (29.1%) 0.070
Tocilizumab 103 (18.0%) 19 (5.9%) 122 (13.6%) < 0.001
Infliximab 84 (14.7%) 17 (5.3%) 101 (11.3%) < 0.001
Anakinra 54 (9.4%) 28 (8.7%) 82 (9.2%) 0.701
Abatacept 39 (6.8%) 17 (5.3%) 56 (6.3%) 0.356
Canakinumab 28 (4.9%) 10 (3.1%) 38 (4.2%) 0.200
Rituximab 26 (4.5%) 3 (0.9%) 29 (3.2%) 0.003
Golimumab 14 (2.4%) 6 (1.9%) 20 (2.2%) 0.566
Certolizumab 4 (0.7%) 1 (0.3%) 5 (0.6%) 0.453
Other biologic agents 2 (0.3%) 1 (0.3%) 3 (0.3%) 1.000
Data are n (%) or medians with IQR range. Drugs refer to their administration at any time during the patient’s history and are sorted by their descending
frequencies. *The adjudicated patients are represented by those with opportunistic infections as per the provisional list of opportunistic pathogens/presentations
(step 1), and very severe/severe or serious non-opportunistic infections. The remaining ones represent the not adjudicated patients. JIA juvenile idiopathic arthritis,
FU follow-up, RF rheumatoid factor, DMARDs disease-modifying anti-rheumatic drugs
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[39]. The final list of opportunistic infections/presenta-
tions could constitute a future reference for researchers,
pharmaceutical companies, and regulatory authorities
dealing with pharmacovigilance issues.
The introduction of biologics in the 2000s for the treat-
ment of JIA has dramatically changed the prognosis of
children affected by JIA, but has also raised concerns on
the possible risk of infections and other safety events in
these patients. Despite the widespread use of these drugs,
there is still a lack of knowledge regarding the assessment
of the long-term safety of the biologics in JIA. In this con-
text, the role of national and international registries be-
comes an important source of data [39, 45–47].
The Pharmachild international registry has the advan-
tage of combining information from different countries
based on real clinical data. In Pharmachild, infections
occurred in about 11% of patients with JIA [39], and
among them, it is of primary importance to identify the
opportunistic infections that may impose a serious threat
to the immunocompromised child. This is not an easy
task, because apparently there is a large gap between
what treating pediatric rheumatologists feel can be con-
sidered as an OI and what a panel of experts adjudicates
as such. While most serious infections also occur in the
healthy population, some events are more frequent or
severe in case of immunosuppression. Conversely, some
infections, such as tuberculosis, more common in im-
munocompromised children, may affect also the general
population, although usually less severely [48]. Consider-
ing these difficulties in correctly defining OI, we made
an effort to produce a document defining OI specifically
in children with JIA on immunosuppression. Something
similar was recently developed by a specialized Commit-
tee convened in the adult setting to define OI in adults
and children with immune-mediated diseases on bio-
logics [32]. With the same approach, our panel of spe-
cialists voted, through a three-step Delphi procedure, for
a correct definition of definite and probable OI and sub-
sequently produced a list of OI by cross-matching the
provisional list produced by consensus with the Pharma-
child data. In a first phase of our study, among the
Pharmachild patients, a considerable percentage of infec-
tions (119/682, 17.4%) was adjudicated as opportunistic.
When we matched the provisional list of OI with the pa-
tients’ clinical information, it became clear that other
than events with full agreement between the SAC and
the list, which could be considered either “confirmed
OI” (106/682, 15.5%) or “non-confirmed OI” (274/682,
40.2%), there was a considerable number (299/682,
43.8%) of debatable infections due to the specific pa-
tient’s history and/or the pathogen presentation, and
classified as “possible/patient and/or pathogen-related
OI.” The best example is represented by herpes zoster
(Tables 4 and 5). Varicella zoster presentation was in-
cluded among the “confirmed OI,” as suggested in the
majority of the literature in this issue [49–51]. However,
primary varicella infection, frequently observed in our
population (155/682, 22.7%), was included among the
“possible/patient and/or pathogen-related OI” rather
than “definite OI” due to the high incidence in healthy
non-vaccinated children and its usually non-complicated
presentation. This group of patients highlights the diffi-
culties in defining OI in children with JIA on treatment,
but also the critical importance of providing a reference
document listing those infections that should always be
considered as opportunistic in these patients, with pos-
sible implications for treatment or prophylaxis. Half of
the patients with herpes zoster infections had varicella in
their history indicating a possible subsequent reactiva-
tion of the virus due to a transient immunosuppressive
condition. One patient developed varicella despite vac-
cination while 2 patients had herpes infection despite
previous vaccination, without manifesting primary vari-
cella. This observation may give rise to speculations
about a possible increase in zoster infections in JIA
population under immunosuppressive therapy through
varicella infection as well as herpes zoster reactivation.
Limited data are available on vaccinations for other in-
fections such as papillomavirus, which occurred only in
2 patients not previously vaccinated. Therefore, it would
be worthwhile to develop further studies focused specif-
ically on this topic, in order to understand if
Table 3 Frequency of answers by the SAC. Consensus by the majority of the Safety Adjudication Committee (SAC) members (3/5)
was required on the first 3 questions, so that 689 events were adjudicated by the panel. Among them, 682 were confirmed as
infections and retained for the analysis
Question for adjudication by the SAC Yes No Impossible to determine Total with consensus
1. Based on the information provided, do you confirm
that this patient had an infection?
682 (99%) 0 7 (1%) 689 (100%)
2. Is this infection common? 603 (88.4%) 78 (11.4%) 1 (0.2%) 682 (100%)
3. Is this an opportunistic infection? 119 (17.4%) 556 (81.5%) 7 (1%) 682 (100%)
4. Was the treatment appropriate for the infection? 484 (77.1%) 4 (0.6%) 140 (22.3%) 628 (92%)
5. Could the event be possibly related to any of the
drug(s) taken at the time of the event?
307 (76.2%) 70 (17.4%) 2 (0.5%) 403* (59%)
*n = 24 were events without answers for the lack of consensus by the panel (less than 3/5 experts agreeing on the answer)
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vaccinations may maintain a protective immune status
in JIA patients under treatment or not. It would also be
interesting to investigate how to identify patients with
JIA at risk for developing OI, but this would require
further comparative studies on the immune status in JIA
patients receiving different immunosuppressive treat-
ments. Per definition, a definite OI can occur in patients
without recognized forms of immunosuppression but its
presence indicates a potential or likely alteration in host
immunity. Therefore, it is worthwhile to consider each
OI as relevant and representing a potential risk for the
JIA patient’s life, thus requiring a prompt treatment. In
fact, to the best of our knowledge, there are no studies
indicating who is at major risk of complications due to
an opportunistic pathogen among JIA patients on im-
munosuppressive therapy. The use of an immune
screening to help primary care practitioners who may
care for, diagnose, and manage infections is already con-
solidated in clinical practice [45]. In our study, we found
no specific level of immunosuppression indicating an in-
creased frequency of infections such as Pneumocystis jir-
ovecii, although too little data are available on this issue
and further analysis is needed to understand the correl-
ation between immune status and OI in patients with
autoimmune diseases.
Biologics and methotrexate were often seen at the time
of a “confirmed OI.” Nevertheless, a comparative study
about the role of immunosuppressive drugs would re-
quire a larger population and a deeper analysis, which
was not the aim of the present manuscript.
Besides those pathogens confirmed as OI and non- or
possible OI by the panel on the basis of the Pharmachild
real patients’ data, there are also pathogens (e.g., Nocar-
dia) that have been included in the list of definite/pos-
sible OI (Table 1) by consensus, although they were not
identified in Pharmachild. These infections, apparently
uncommon since there was none in such a large data-
base, should be considered potential indicators of alter-
ations in host immunity when present in JIA patients
and deeply investigated by the physician of the center in
order to prevent possible complications in these
patients.
The current literature provides similar evidence, but
remains controversial for the majority of OI. Beukelman
et al. in 2012 reviewed US Medicaid data comparing the
incidence of bacterial infections requiring hospitalization
in children with and without JIA [1, 30]. The infection
rate was already twice as high in patients with JIA not
exposed to treatments, compared to children with
attention-deficit hyperactivity disorder (ADHD) used as
controls [30]. The same author 1 year later re-analyzed
the same data by comparing the incidence rate of se-
lected OI among children with and without JIA. Cocci-
dioides, Salmonella, and herpes zoster were more
common among children with JIA [31]. Among the 15
pathogens they used to define their list of OI, all in our
provisional OI list (Table 1), only herpes zoster, tubercu-
losis, Pneumocystis, and Aspergillus were confirmed in
Table 4 Frequency of the 106 infections classified as “confirmed
OI” by the SAC. Opportunistic infections (OI) were classified as
“confirmed OI” after the evaluation of the cases available in
Pharmachild with full agreement between the Safety
Adjudication Committee (SAC) and the list of provisional
pathogens/presentations. Data are presented as per the
MedDRA High Level and Preferred Term and sorted by
frequencies in descending order
HLT-PT name “Confirmed OI”
N = 106
Patients
N = 93*
Herpes viral infections 72 (68%) 64 (68.8%)
Herpes zoster 66 (91.6%)
Herpes ophthalmic 2 (2.8%)
Ophthalmic herpes zoster 2 (2.8%)
Herpes virus infection 1 (1.4%)
Herpes zoster oticus 1 (1.4%)
Tuberculous infections 11 (10.4%) 10 (10.8%)
Pulmonary tuberculosis 6 (54.5%)
Disseminated tuberculosis 4 (36.4%)
Bone tuberculosis 1 (9.1%)
Candida infections 9 (8.5%) 9 (9.7%)
Oral candidiasis 4 (44.4%)
Candida pneumonia 2 (22.2%)
Balanitis candida 1 (11.1%)
Candida sepsis 1 (11.1%)
Esophageal candidiasis 1 (11.1%)
Papilloma viral infections 4 (3.8%) 2 (2.2%)
Vulvovaginal human
papilloma virus infection
3 (75%)
Anogenital warts 1 (25%)
Pneumocystis infections 4 (3.8%) 4 (4.3%)
Pneumocystis jirovecii
pneumonia
4 (100%)
Cytomegaloviral infections 3 (2.8%) 3 (3.2%)
Cytomegalovirus mononucleosis 1 (33.3%)
Cytomegalovirus viraemia 1 (33.3%)
Pneumonia cytomegaloviral 1 (33.3%)
Aspergillus infections 1 (0.9%) 1 (1.1%)
Bronchopulmonary aspergillosis 1 (100%)
Leprous infections 1 (0.9%) 1 (1.1%)
Leprosy 1 (100%)
Infections NEC 1 (0.9%) 1 (1.1%)
Infection in an
immunocompromised host
1 (100%)
*One patient may have been suffering from different OI over time
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Table 5 Frequency of the “confirmed non-OI” and “possible/patient and pathogen-related OI” adjudicated by the SAC
HLT-PT name
N (%)
“Confirmed non-OI”
N = 59 (%)
“Possible/patient and pathogen-related OI”
N = 299 (%)
Herpes viral infections, N = 193 (64.5)
Varicella 128 (42.8)
Oral herpes 30 (10.1)
Varicella zoster virus infection 24 (8.1)
Other herpes infections 11 (3.7)
Epstein-Barr viral infections, N = 38 (12.7)
Epstein-Barr virus infection 22 (7.4)
Other EBV infections 16 (5.3)
Tuberculous infections, N = 18 (6.0)
Latent tuberculosis 12 (4.1)
Tuberculosis 6 (2.0)
Candida infections, N = 8 (2.7)
Vulvovaginal candidiasis 6 (2.1)
Other candidiasis 2 (0.6)
Influenza viral infections, N = 14 (23.7)
Influenza 13 (22)
H1N1 influenza 1 (1.7)
Streptococcal infections, N = 14 (23.7)
Scarlet fever 4 (6.7)
Pharyngitis streptococcal 3 (5.1)
Other streptococcal infections 7 (11.9)
Salmonella infections, N = 9 (3.0)
Gastroenteritis salmonella 6 (2.1)
Other Salmonella infections 3 (1.0)
Molluscum contagiosum viral infections, N = 7(2.3) (2.3)
Molluscum contagiosum 7 (2.3)
Staphylococcal infections, N = 5 (8.5)
Staphylococcal sepsis 2 (3.4)
Other staphylococcal infections 3 (5.1)
Escherichia infections, N = 4 (6.8)
Escherichia pyelonephritis 3 (5.1)
Cystitis Escherichia 1 (1.7)
Skin structures and soft tissue infections, N = 3 (5.1) (5.1)
Impetigo 3 (5.1)
Bordetella infections, N = 3 (5.1)
Pertussis 2 (3.4)
Bordetella infection 1 (1.7)
Mycoplasma infections, N = 3 (5.1)
Mycoplasma infections 3 (5.1)
Yersinia infections, N = 2 (3.4)
Gastroenteritis yersinia 2 (3.4)
Other infections (HLT frequency < 2%) 11 (18.6) 26 (8.7)
Clinical presentations were removed because of the lack of the specified pathogen. Data are presented as per the MedDRA High Level Term and
Preferred Term and sorted by frequencies in descending order. Only pathogens with HLT % ≥ 2% are presented in details. The full listing is
available in additional table 1. SAC Safety Adjudication Committee
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our final list of “confirmed OI.” The remaining cases
were included in the “possible/patient and/or pathogen-
related OI” list. Interestingly, the authors included pri-
mary varicella infection in the OI only if the affected pa-
tient received critical care services during the
hospitalization. An increased risk of herpes zoster infec-
tion was confirmed in many studies, both in JIA [49]
and in adult rheumatoid arthritis [52]. More recently,
Aeschlimann et al. studied, through a meta-analysis,
whether treatment with biologics during clinical trial
study periods increased the risk of serious infections in
children with JIA. On a total of 19 trials accounting for
21 individual studies, 17 serious infections were reported
among 810 children, with bronchopulmonary infections
and varicella being the most frequent events [53]. Be-
sides this evidence, the role of other opportunistic path-
ogens still needs to be further investigated, as well as the
comparison of OI among large registries. Recently, Swart
et al. have provided a comparison between Pharmachild
and national registries. In particular, a comparable per-
centage of serious AE has been found between Pharma-
child and the German registry Biker (6.9% and 7.4%,
respectively), with an overlapping frequency of infection
and infestations among all AEs (29.4–30.1%). Infections
also resulted the most frequent ESI in both registries
(75.3–89%). Interestingly, among OI, tuberculosis af-
fected 27 cases in Pharmachild and none in BiKer, al-
though this could be explained by the different
geographic distribution of the patients [39].
A limitation of our study is that Pharmachild is mainly
a European registry, although it includes countries
worldwide. This means that our results mainly depict
the European scenario of OI. A future manuscript will
focus on those factors increasing the risk of OI through
appropriate modeling to identify the risk factor for OI
infection including disease duration, drugs, comorbidi-
ties, etc.
Conclusions
In conclusion, almost 1/5 of all severe and/or serious in-
fections in JIA patients on immunosuppressive therapy
are opportunistic. The most frequent opportunistic path-
ogens were herpes virus (excluding non-complicated pri-
mary varicella), mycobacterial, and Candida infections.
We provided with our work a list of “confirmed OI” in
children with JIA on immunosuppressive therapy that
could be used as possible reference document for future
works on pharmacovigilance in children with JIA on im-
munosuppressive therapy and a list of infections that
could possibly display an opportunistic nature related to
the patient’s history and/or the pathogen presentation.
More clarity in the understanding of OI in children with
JIA on immunosuppressant will help in deciding on
immunosuppressive treatment and prophylaxis in this
group of patients.
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